Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell and Roger Green to discuss the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021 and some personal experiences that made PFDD such a priority.
Global Liver Institute Founder, President, and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join Stephen Harrison, Louise Campbell, and Roger Green to review the ground-breaking NASH Patient-Focused Drug Development meeting held on November 4, 2021.
In the third conversation from SurfingNASH’s AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss a range of issues in the latter days of the conference, all loosely related to NASH Patient Management.
In the first conversation from SurfingNASH’s AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to focus on some of the basic NASH Science presentations during the first two days of the meeting.
Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss key presentations at AASLD 2021 and preview SurfingNASH’s coverage of the event. This virtual meeting runs from November 12-15 and is scheduled on East Coast time.
Alina Allen and Ian Rowe lead the Surfers in considering biopathological shortcomings in fibrosis as a solitary endpoint. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about the availability of subgroup analysis.
Alina Allen and Stephen Harrison spearhead a discussion on how MRE results can provide a foundation for developing Subpart H Clinical Trial Endpoints from non-invasive testing data. Their comments stem from Alina’s presentation of the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about availability of subgroup analysis.
Alina Allen and Ian Rowe join the Surfers to discuss the recent Mayo Clinic paper, “MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.” In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about availability of subgroup analysis.
Professors Alina Allen and Ian Rowe join the Surfers to discuss our ability to predict long-term outcomes using MR Elastography. The conversation flows around Mayo Clinic’s recent Hepatology publication, “MRE for prediction of long term progression and outcome in chronic liver disease.
The entire panel enters a discussion around histopathology’s shortcomings, ranging from the fact that the NAFLD Activity score does not correlate with liver function to inconsistencies in reading all elements of biopsy.
